-+ 0.00%
-+ 0.00%
-+ 0.00%

GSK drops camlipixant RCC development after mixed Phase III results

PUBT·07/17/2026 10:51:38
Listen to the news
GSK drops camlipixant RCC development after mixed Phase III results
  • GSK will stop development of camlipixant for refractory chronic cough following limited efficacy across the CALM phase III program.
  • CALM-1 supported 50 mg twice daily at week 12, while CALM-2 failed to reach significance at week 24; 25 mg twice daily missed in both.
  • Results will be submitted for future presentation or publication to inform ongoing research into refractory chronic cough.
  • The phase IIb BALANCE trial will continue to test camlipixant in IBS-D and IBS-M.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GSK plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001654954-26-006705), on July 17, 2026, and is solely responsible for the information contained therein.